Literature DB >> 26828133

Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.

Iris Eke1, Adeola Y Makinde2, Molykutty J Aryankalayil2, Mansoor M Ahmed3, C Norman Coleman4.   

Abstract

New technologies enabling the analysis of various molecules, including DNA, RNA, proteins and small metabolites, can aid in understanding the complex molecular processes in cancer cells. In particular, for the use of novel targeted therapeutics, elucidation of the mechanisms leading to cell death or survival is crucial to eliminate tumor resistance and optimize therapeutic efficacy. While some techniques, such as genomic analysis for identifying specific gene mutations or epigenetic testing of promoter methylation, are already in clinical use, other "omics-based" assays are still evolving. Here, we provide an overview of the current status of molecular profiling methods, including promising research strategies, as well as possible challenges, and their emerging role in radiation oncology. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Molecular profiling; Precision medicine; Radiation oncology; Targeted therapy

Mesh:

Substances:

Year:  2016        PMID: 26828133      PMCID: PMC4967037          DOI: 10.1016/j.canlet.2016.01.041

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  125 in total

Review 1.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

2.  Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines.

Authors:  Joana Balça-Silva; Sílvia Sousa Neves; Ana Cristina Gonçalves; Ana Margarida Abrantes; João Casalta-Lopes; Maria Filomena Botelho; Ana Bela Sarmento-Ribeiro; Henriqueta Coimbra Silva
Journal:  Anticancer Res       Date:  2012-05       Impact factor: 2.480

3.  Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples.

Authors:  Mitchell J Frederick; Amy J VanMeter; Mayur A Gadhikar; Ying C Henderson; Hui Yao; Curtis C Pickering; Michelle D Williams; Adel K El-Naggar; Vlad Sandulache; Emily Tarco; Jeffrey N Myers; Gary L Clayman; Lance A Liotta; Emanuel F Petricoin; Valerie S Calvert; Valentina Fodale; Jing Wang; Randal S Weber
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

4.  Quantitative proteomics unveiled: Regulation of DNA double strand break repair by EGFR involves PARP1.

Authors:  Laura Myllynen; Marcel Kwiatkowski; Lisa Gleißner; Britta Riepen; Konstantin Hoffer; Marcus Wurlitzer; Cordula Petersen; Ekkehard Dikomey; Kai Rothkamm; Hartmut Schlüter; Malte Kriegs
Journal:  Radiother Oncol       Date:  2015-09-25       Impact factor: 6.280

5.  A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).

Authors:  Rogerio Lilenbaum; Michael Samuels; Xiaofei Wang; Feng Ming Kong; Pasi A Jänne; Gregory Masters; Sreedhar Katragadda; Lydia Hodgson; Jeffrey Bogart; Jeffrey Bradley; Everett Vokes
Journal:  J Thorac Oncol       Date:  2015-01       Impact factor: 15.609

Review 6.  Current clinical trials testing combinations of immunotherapy and radiation.

Authors:  Marka Crittenden; Holbrook Kohrt; Ronald Levy; Jennifer Jones; Kevin Camphausen; Adam Dicker; Sandra Demaria; Silvia Formenti
Journal:  Semin Radiat Oncol       Date:  2015-01       Impact factor: 5.934

7.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

8.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Authors:  Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

9.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

10.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Authors:  Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit
Journal:  Nature       Date:  2011-11-23       Impact factor: 49.962

View more
  8 in total

1.  The Radiation Stress Response: Of the People, By the People and For the People.

Authors:  C Norman Coleman
Journal:  Radiat Res       Date:  2017-01-24       Impact factor: 2.841

Review 2.  Exploiting Gene Expression Kinetics in Conventional Radiotherapy, Hyperfractionation, and Hypofractionation for Targeted Therapy.

Authors:  Adeola Y Makinde; Iris Eke; Molykutty J Aryankalayil; Mansoor M Ahmed; C Norman Coleman
Journal:  Semin Radiat Oncol       Date:  2016-07-05       Impact factor: 5.934

3.  Long-term Tumor Adaptation after Radiotherapy: Therapeutic Implications for Targeting Integrins in Prostate Cancer.

Authors:  Iris Eke; Adeola Y Makinde; Molykutty J Aryankalayil; Jessica L Reedy; Deborah E Citrin; Sunita Chopra; Mansoor M Ahmed; C Norman Coleman
Journal:  Mol Cancer Res       Date:  2018-07-24       Impact factor: 5.852

4.  Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example.

Authors:  Iris Eke; Adeola Y Makinde; Molykutty J Aryankalayil; Veit Sandfort; Sanjeewani T Palayoor; Barbara H Rath; Lance Liotta; Mariaelena Pierobon; Emanuel F Petricoin; Matthew F Brown; Jayne M Stommel; Mansoor M Ahmed; C Norman Coleman
Journal:  Mol Cancer Ther       Date:  2017-08-11       Impact factor: 6.009

Review 5.  Radiation-induced Adaptive Response: New Potential for Cancer Treatment.

Authors:  C Norman Coleman; Iris Eke; Adeola Y Makinde; Sunita Chopra; Sandra Demaria; Silvia C Formenti; Shannon Martello; Michelle Bylicky; James B Mitchell; Molykutty J Aryankalayil
Journal:  Clin Cancer Res       Date:  2020-06-17       Impact factor: 13.801

6.  Radiotherapy alters expression of molecular targets in prostate cancer in a fractionation- and time-dependent manner.

Authors:  Iris Eke; Molykutty J Aryankalayil; Michelle A Bylicky; Adeola Y Makinde; Lance Liotta; Valerie Calvert; Emanuel F Petricoin; Edward E Graves; C Norman Coleman
Journal:  Sci Rep       Date:  2022-03-03       Impact factor: 4.996

Review 7.  Radiotherapy for Oligometastatic Lung Cancer.

Authors:  Derek P Bergsma; Joseph K Salama; Deepinder P Singh; Steven J Chmura; Michael T Milano
Journal:  Front Oncol       Date:  2017-09-19       Impact factor: 6.244

8.  Do We Need a New Approach to Cancer Biology Education for Radiation Oncology Residents?

Authors:  Srinivasan Vijayakumar; Maurice King; Mary R Nittala; Roy J Duhe
Journal:  Cureus       Date:  2021-12-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.